Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03332264
Other study ID # SP01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 30, 2017
Est. completion date December 12, 2023

Study information

Verified date February 2024
Source InnoRa GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with peripheral artery disease will be treated with either drug coated balloon catheter, drug coated stent or uncoated stent.


Description:

Patients with chronic stenotic or occlusive atherosclerotic disease and lesions of at least 13 cm length in the SFA or Arteria poplitea segment 1 will be randomized to either treatment with paclitaxel coated balloon catheter, paclitaxel coated stent or bare nitinol stent. Vessel patency will be evaluated by quantitative angiography after 12 months. Clinical follow-ups will be done until 36 months post-intervention.


Recruitment information / eligibility

Status Completed
Enrollment 224
Est. completion date December 12, 2023
Est. primary completion date January 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - PAOD and Rutherford classes 2 - 4 (pain-free walking distance <500 m) - eligible for peripheral revascularization by means of PTA - peripheral lesions in the superficial femoral artery (SFA) and / or the PI-segment of the popliteal artery (A.pop.) - minimum diameter stenosis of =70% - treatment length at least 15 cm (lesion length at least 13 cm) - maximum of lesions to be treated should be 2 (all treated lesions should be treated within the randomization to the study group, i.e. either coated balloon catheters or coated stents or bare nitinol stents); in case of two lesions matching the eligibility criteria, the one presenting the worst attributes (length and stenosis degree) should be chosen as target lesion - long diffuse stenosis with or without occlusions may only be divided in separate lesions if non-stenotic (i.e. <50% stenosis) segments in between the lesions extent to >2 cm, otherwise vessel segments will be treated as a single extended lesion - eligible for an operative vascular intervention in case of complications during the PTA Exclusion Criteria: - Rutherford class 1,5 or 6 - more than two stenotic lesions in the target vessel requiring treatment - inflow lesion (proximal to the study lesion) with flow limitation not being successfully treated prior to the study lesion - in-stent restenosis of the study lesion - strongly calcified lesions with circumferential presence of calcifications and a lesion calcification length of >4 cm - reference vessel diameter <4 mm and >6 mm - guide wire could not be successfully advanced across the lesion - lesions below the knee requiring treatment - target lesion is located in the PII-segment of the popliteal artery (A.pop.) or within a bypass graft - acute thrombosis of the study lesion requiring lysis or thrombectomy prior to the treatment of the study lesion - potential loss of leg due to critical or acute ischemia - no patent distal run-off vessel - medical reason against double anti-platelet therapy in anti-coagulated patient, e.g., receiving coumarine or conditions which prevent the intake of the double anti-platelet therapy for two months - female patient who is pregnant or lactating - under 18 years of age - patients under administrative or judicial custody (§20 Act on medical Devices, Germany) - expected life span of less than 24 months

Study Design


Related Conditions & MeSH terms


Intervention

Device:
SeQuent Please OTW
Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
Eluvia Vascular Stent System
Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
Nitinol stent
Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent

Locations

Country Name City State
Austria Medizinische Universität Graz Graz
Germany Klinikum Arnsberg, Karolinen-Hospital Arnsberg
Germany Herzzentrum Bad Krozingen Bad Krozingen
Germany Ihre-Radiologen Standort Franziskus-Krankenhaus Berlin
Germany Ihre-Radiologen Standort Jüdisches Krankenhaus Berlin
Germany Vivantes Klinikum Neukölln Berlin
Germany Diakonissenkrankenhaus Flensburg Flensburg
Germany SANA Kliniken Lübeck Lübeck
Germany Universitätklinikum Lübeck Lübeck
Germany RoMed Klinikum Rosenheim Bayern

Sponsors (3)

Lead Sponsor Collaborator
InnoRa GmbH B. Braun Melsungen AG, Boston Scientific Corporation

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Event-free survival absence from target lesion revascularization, amputations and death 6, 12, 24, 36 months
Other Walking distance assessed in m and compared to baseline value 6, 12, 24, 36 months
Primary Percent diameter stenosis at 1 year post intervention in successfully treated patients by quantitative angiography 12 +/- 2 months
Secondary Late Lumen Loss by quantitative angiography 12 months
Secondary Binary restenosis by DUS 6,12, 24, 36 months
Secondary Target lesion revascularization number of re-interventions at target lesion 6, 12, 24, 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Completed NCT02834806 - BIONICS Israel Trial N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT00555659 - Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody Fusions N/A
Withdrawn NCT00543348 - RCT of the Cutting Balloon Versus a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses N/A
Completed NCT00205101 - Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion
Terminated NCT04370041 - Dokimos Plus Aortic Valve Implant in 80 Patients Diagnosed With a Heart Valve Disease and Requiring Valve Replacement N/A
Recruiting NCT05053932 - Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia
Completed NCT02373852 - PMS Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention
Completed NCT01970579 - Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter Phase 3
Completed NCT01873586 - OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion N/A
Completed NCT00540813 - Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions N/A
Recruiting NCT00496639 - Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes N/A
Terminated NCT00254852 - Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft N/A
Enrolling by invitation NCT05583305 - Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
Completed NCT02018445 - Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion N/A
Withdrawn NCT03327272 - Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion Phase 3
Completed NCT04698512 - MAgicTouch™ Intervention Leap for Dialysis Access (MATILDA) Trial
Active, not recruiting NCT02428582 - Covered Stents Versus Bare-Metal Stents N/A